Table 1.
Patient, treatment, and response characteristics (n = 243)
| Characteristic | No. (%) |
|---|---|
| Median age at enrollment (range), y | 60 (18-82) |
| Sex | |
| Male | 119 (49.0) |
| Female | 124 (51.0) |
| ECOG | |
| 0 | 49 (20.2) |
| 1 | 193 (79.4) |
| 2 | 1 (0.4) |
| Education level | |
| Elementary school | 5 (2.1) |
| High school | 76 (31.3) |
| Postgraduate (nonuniversity) | 56 (23.0) |
| University | 106 (43.6) |
| English as primary language | |
| Yes | 217 (89.3) |
| No | 26 (10.7) |
| Tumor type | |
| Gastrointestinal | 77 (31.7) |
| Head and neck | 32 (13.2) |
| Breast | 26 (10.7) |
| Genitourinary | 24 (9.9) |
| Gynecological | 21 (8.6) |
| Melanoma | 19 (7.8) |
| Lung | 18 (7.4) |
| Sarcoma | 18 (7.4) |
| Other | 8 (3.3) |
| RMI score | |
| 0-1 | 173 (71.2) |
| 2-3 | 70 (28.8) |
| Prior treatments | |
| 0 | 13 (5.3) |
| 1 | 62 (25.5) |
| 2 | 87 (35.8) |
| ≥3 | 81 (33.3) |
| Monotherapy or combination | |
| Monotherapy | 91 (37.4) |
| Combination | 152 (62.6) |
| Treatment type by group | |
| Immunotherapy based | 160 (65.8) |
| Targeted based | 60 (24.7) |
| Immuno-targeted combination | 23 (9.5) |
| Best responsea | |
| Complete response | 3 (1.4) |
| Partial response | 18 (8.2) |
| Stable disease | 79 (36.1) |
| Progressive disease | 117 (53.4) |
aRECIST evaluable population (n = 219). Screen fail; n = 24 (9.9%); not evaluable, n = 2 (0.9%); overall response rate (complete response + partial response) = 9.6%. ECOG = Eastern Cooperative Oncology Group; RMI = Royal Marsden Index.